-
Adipocyte-Targeted CRISPRi for Obesity and Insulin Resistanc
2026-09-22
The reference study combines Fabp4-directed CRISPR interference with an adipose-targeting peptide to repress gene expression selectively in mature white adipocytes. In obese mice, this nonviral strategy reduced body weight and inflammation while improving hepatic steatosis and insulin resistance, providing a proof of concept for tissue-directed metabolic gene regulation.
-
CENPI, Wnt/β-Catenin, and Breast Cancer Progression
2026-09-22
Wu and colleagues identify centromere protein I (CENPI) as an overexpressed driver of breast cancer progression and connect its activity to Wnt/β-catenin signaling. By combining clinical datasets, cellular and xenograft models, RNA sequencing, and pathway reporter assays, the study provides a mechanistic framework for evaluating CENPI as a biomarker and therapeutic target.
-
AMG 9810 Workflows for TRPV1 Research
2026-09-21
AMG 9810 provides a reversible, selective way to separate TRPV1-driven calcium and CGRP responses from broader sensory-cell stress signals. This workflow combines concentration-controlled antagonism, paired functional readouts, and metabolic-stress controls for more rigorous pain mechanism research and sensory neuron signaling studies.
-
Two-Component BoNT-Like Toxins in P. ghonii
2026-09-21
Lee and colleagues identified PG1 and PG2, unusual two-component botulinum neurotoxin–like proteins from Paeniclostridium ghonii that selectively cleave insect SNAP25. Structural, biochemical, and insect-injection experiments connect their architecture to host-specific toxicity and suggest a foundation for studying new bacterial biocontrol proteins.
-
EDTA-Free Protease Inhibitor Cocktail K4002
2026-09-20
The Protease Inhibitor Cocktail is an EDTA-Free Protease Inhibitor solution for broad-spectrum control of proteolysis during cell and tissue extraction. Its 100X formulation in DMSO targets serine, cysteine, acidic, aminopeptidase, and metalloprotease activities for protein-focused workflows.
-
Vernakalant PK/PD in Acute Atrial Fibrillation
2026-09-19
The 2011 population pharmacokinetic–pharmacodynamic study integrated data from five clinical trials to define exposure–response relationships for QTcF and systolic blood pressure during vernakalant treatment of atrial fibrillation or atrial flutter. Its key contribution was showing that QTcF exposure–response differed according to conversion status, while hypotension risk was driven mainly by baseline blood pressure rather than plasma drug concentration.
-
Protecting the Proteome in Liver Regeneration
2026-09-18
A translational perspective on how proteolysis control strengthens liver-regeneration studies, using SPP2 biology to show why EDTA-free sample preparation can protect mechanistic interpretation without overstating experimental evidence.
-
Human iPSC Intestinal Organoids for Pharmacokinetics
2026-09-18
This 2025 study establishes a direct three-dimensional culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The organoids can be maintained, cryopreserved, and converted into two-dimensional intestinal epithelial monolayers containing metabolically competent enterocytes, providing a more human-relevant platform for oral drug absorption and pharmacokinetic research.
-
(1S,3R)-RSL3: GPX4 Inhibitor
2026-09-17
Explore RSL3 as a glutathione peroxidase 4 inhibitor through a radiosensitivity-focused framework linking ferroptosis, hypoxia, lipid droplets, and tumor biology. This article translates recent nasopharyngeal carcinoma findings into practical assay decisions without treating RSL3 as a one-size-fits-all ferroptosis readout.
-
Biotin-tyramide: Practical TSA Workflow and QC
2026-09-17
Biotin-tyramide is a biotin phenol reagent for HRP-dependent tyramide signal amplification in fixed-cell and tissue workflows, including immunohistochemistry (IHC) and in situ hybridization (ISH). This guide covers preparation, controls, storage, and troubleshooting; it should not be treated as a validated diagnostic protocol or as evidence for untested targets, tissues, or reaction conditions.
-
Protease Inhibitor Cocktail for Mitochondrial Assays
2026-09-16
An EDTA-free Protease Inhibitor Cocktail protects mitochondrial-stress samples while preserving compatibility with phosphorylation assays, native complexes, and kinase workflows. This practical guide connects mitocytosis research with reproducible protein extraction, assay design, and troubleshooting.
-
Protease Inhibitor Cocktail: Protecting Lipolysis Data
2026-09-16
Discover how a Protease Inhibitor Cocktail can preserve DFCP1–ATGL interactions and phospho-sensitive readouts without obscuring assay biology. This guide develops an EDTA-aware workflow for extracting interpretable lipid-droplet proteins from cells and tissues.
-
Protease Inhibitor Cocktail for Plant Protein Stability
2026-09-15
A practical guide to using an EDTA-free, 100X DMSO formulation to preserve plant proteins during infection, signaling, and immunoprecipitation workflows. The article connects protein degradation inhibition with the emerging CMV–m6A mechanism and shows how to improve extraction, assay compatibility, and troubleshooting without treating the reagent as an RNA stabilizer.
-
CS-NAC Nanoparticles Suppress Ferroptosis in OA
2026-09-15
A 2025 Small Science study developed chondroitin sulfate-modified PLGA nanoparticles to deliver N-acetylcysteine directly to chondrocytes. The formulation improved joint retention, maintained glutathione and GPX4 activity, suppressed ferroptosis, and protected cartilage more effectively than free NAC or nontargeted nanoparticles in a murine osteoarthritis model.
-
EZ Cap™ Cas9 mRNA (m1Ψ) in Cell Assays
2026-09-14
Learn how EZ Cap™ Cas9 mRNA (m1Ψ), SKU R1014, can support more interpretable CRISPR-Cas9 experiments involving cell viability, proliferation, and cytotoxicity readouts. This scenario-based guide covers reagent selection, controls, handling, assay compatibility, and interpretation without overstating product-specific performance.